

Sede

Auditorium I Clinica Medica
"Sapienza" Università di Roma
I Facoltà di Medicina e Chirurgia
Viale del Policlinico, 155 - Roma

Segreteria Scientifica

C.Stefanutti
Sez. ed Amb. di Plasmaferesi Terapeutica
Dipartimento di Clinica e Terapia Medica
"Sapienza" Università di Roma
Az. Policlinico Umberto I
V.le del Policlinico, 155 - 00161 Roma
Tel. (Fax) 06 49970578 - plasmaferesi@tin.it

Segreteria Organizzativa

Centro Italiano Congressi CIC
Corso Trieste, 42 - 00198 Roma
Tel. 06 8412673 - Fax 06 8412687
congressi@gruppocic.it
www.centroitalianocongressi.it

Partecipazione

La partecipazione del Corso è gratuita.
L'accettazione delle iscrizioni seguirà un criterio di priorità temporale sulla base della data di arrivo dell'adesione alla Segreteria Organizzativa.
Si prega comunicare la propria adesione all'indirizzo di posta elettronica:
meetinglipidclub2010@gruppocic.it

Accreditamento E.C.M.

Il Corso rientra nella normativa che regola l'E.C.M.
Il relativo punteggio ai fini dei Crediti formativi verrà determinato dal Ministero della Salute.
Il rilascio dei crediti è subordinato alla partecipazione all'intera durata dei lavori e alla consegna del questionario di valutazione dell'apprendimento debitamente compilato e firmato.



Centro Italiano Congressi C.I.C.

LIPIDCLUB & Therapeutic Apheresis 2010

Interdisciplinary Educational Forum

Updating in Apheresis and Atherosclerosis Research



Roma, May 7, 2010

Friday, May 7, 2010

MORNING

Opening Conference

Prof. L. Frati

Magnifico Rettore della "Sapienza" Università di Roma

Key lectures



- 09.00 Lp(a) apheresis: evidence and limits
The German experience
- 09.20 Treatment of Symptomatic HyperLp(a) lipoproteinemia
with LDL-apheresis. The Italian reality
- 09.40 Discussion

**LDL-apheresis: evidence from literature & case
report face-to-face session**

- 09.55 Aorta and Coronary Angiographic Follow-up of Children with Severe
Hypercholesterolemia Treated with Low-Density Lipoprotein Apheresis
- 10.10 LDL-apheresis in patients with Familial Autosomal Recessive
Hypercholesterolemia
- 10.25 Indications for LDL-apheresis in Diabetes
- 10.40 Timing Clinical Events in the Treatment of Pancreatitis
and Hypertriglyceridemia with Therapeutic Plasmapheresis
- 10.55 *Coffee Break*

Key lectures

- 11.10 Clinical management of rheumatic diseases: overview and updating
- 11.30 Advances in the use of therapeutic apheresis for the management
of rheumatic diseases

**Therapeutic Plasmapheresis: evidence from literature & case
report face-to-face session**

- 11.40 Predictive criteria for the outcome of patients with acute liver failure
treated with albumin dialysis molecular absorbent recirculating system
- 11.50 Cyclophosphamide and Immunoabsorption Apheresis Treatment of
Lupus Nephritis Nonresponsive to Drug Therapy Alone
- 12.05 Severe necrotizing Polyvasculitis Anticardiolipin -Positive Treated by
Immunoabsorption Apheresis

- 12.20 Immunoabsorption Apheresis and Immunosuppressive Drug Therapy
in the Treatment of Complicated HCV-Related Cryoglobulinemia
- 12.35 Sudden Hearing Loss: clinical experience

13.50 **Round table**

14.20 *Lunch*

AFTERNOON

**Gruppo di Ricerca dello Studio Multicentrico Italiano LDL-afesi:
stato del progetto e prospettive**

Key lectures

- 15.20 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 15.40 Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
- 16.00 Definition and Diagnosis of Heart disease (Atherosclerosis) in
Children and Adolescents
- 16.20 Did Hormone Replacement Therapy Decrease Mortality in Younger
Postmenopausal Woman?
- 16.40 *Coffee Break*
- 16.55 Plurimetabolic syndrome: association of diabetes, dyslipidemia, and
arterial hypertension
- 17.15 Treatment of lipid disorders: Statins and Ezetimibe
- 17.35 Evolution of hypolipidemic drug therapy
- 17.55 Nutraceuticals: Perspectives in Cardiovascular Disease Prevention

Case reports (Topics: Atherosclerosis, Coronary Artery Disease,
Dyslipidemia, Plurimetabolic syndrome, Lipid-Lowering Drugs)

Case reports session (# 4 short speeches)

- 18.30 Multiple lipid-lowering treatment in pediatric patients with
hyperlipidemia
- 18.45 Is the failure of primary prevention in heterozygous familial
hypercholesterolemia reversible?
- 19.00 Multiple therapeutic approach in plurimetabolic syndrome
- 19.15 Renal diseases and dyslipidemia: the pharmacological approach
- 19.30 End of Meeting (CME activities)